Impact of 3 years ivermectin treatment on onchocerciasis in Yanomami communities in the Brazilian Amazon.
In the current study, it was assessed, for the first time, the effect of ivermectin treatment administered twice a year on the prevalence and morbidity of onchocerciasis in the hyperendemic Yanomami communities of the Roraima State (Brazil). Physical and parasitological examinations were carried out every 6 months until six drug rounds of treatment were completed. The coverage during the six rounds of ivermectin treatment ranged from 89% to 92% of the eligible Yanomami population. Overall, comparison of results at pre-treatment with results after six rounds of treatment, the prevalence of infection had declined from 87% to 42% (P<0.0001, CI 95%=0.05-0.22); the community microfilarial load (CMFL) fell from 1.17 to 0.53Mf/mg of skin; and the crude intensity of infection (MFL-Total) decreased from 18.95 to 1.96Mf/mg of skin during the same period (P<0.0001, for both microfilarial loads). Although no significant difference was observed between microfilarial densities in skin snips from iliac crest and scapula after the 6th round of ivermectin treatment it was observed that the prevalence of positive skin snips was significantly higher when skin snips were taken from iliac crest (42%) than from scapula (8%) (P=0.001, CI 95%=3.41-22.67). After six rounds of ivermectin treatments, no significant differences were observed in the prevalences of palpable nodules and of onchodermatitis in relation to pre-treatment prevalences, from 45% to 41% and from 17% to 20% (P>0.05, for both). These findings suggest that mass population treatment should continue without interruption and achieve higher levels of drug coverage in order to alleviate disease manifestations and interrupt infection transmission to hasten the elimination of onchocerciasis in Yanomami communities. In addition, the sensitivity of iliac crest snips for parasitological assessment in epidemiological surveillance of Yanomami communities may increase the acceptance of the population in biopsy sampling and seems to be a good choice for assessing the success of control programs.
Banic
Dalma M
DM
Laboratório de Pesquisas em Malária, Instituto Oswaldo Cruz, Manguinhos, Rio de Janeiro, Brazil. banic@ioc.fiocruz.br
Calvão-Brito
Regina H S
RH
Marchon-Silva
Verônica
V
Schuertez
Joana C
JC
de Lima Pinheiro
Luís Renerys
LR
da Costa Alves
Marilene
M
Têva
Antônio
A
Maia-Herzog
Marilza
M
D000293:Adolescent; D000328:Adult; D000977:Antiparasitic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001938:Brazil; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009855:Onchocerciasis / Q000188:drug therapy* / Q000453:epidemiology*; D015995:Prevalence; D055815:Young Adult
D000977:Antiparasitic Agents; D007559:Ivermectin